<DOC>
	<DOC>NCT00035880</DOC>
	<brief_summary>Trial evaluating the improvement in survival at 180 days of two therapies (Atgam versus ABX-CBL, a monoclonal antibody) in patients with acute graft versus host disease that does not respond to steroid therapy.</brief_summary>
	<brief_title>Study Comparing ABX-CBL (Monoclonal Antibody) Versus Atgam in Patients With Steroid Resistant Acute Graft Versus Host Disease</brief_title>
	<detailed_description />
	<mesh_term>Graft vs Host Disease</mesh_term>
	<criteria>Recipient of single allogeneic stem cell transplant from any donor type Time post transplant less than 100 days Received no treatment for GVHD other than steroids Recipient of second allogeneic stem cell transplant or subsequent lymphocyte product from the donor post transplant IBMTR index less than A Received any murine product in the past Diagnosed with chronic GVHD Received Atgam later than day 10 post transplant Change to prophylactic regimen for acute GVHD within 72 hours of randomization</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2003</verification_date>
	<keyword>Acute graft versus host disease</keyword>
	<keyword>Stem Cell Transplantation</keyword>
</DOC>